MiMedx Group, Inc. (MDXG)
MDXG Stock Price Chart
Explore MiMedx Group, Inc. interactive price chart. Choose custom timeframes to analyze MDXG price movements and trends.
MDXG Company Profile
Discover essential business fundamentals and corporate details for MiMedx Group, Inc. (MDXG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Feb 2008
Employees
837.00
Website
https://www.mimedx.comCEO
Joseph H. Capper
Description
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
MDXG Financial Timeline
Browse a chronological timeline of MiMedx Group, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is $0.07, while revenue estimate is $94.74M.
Earnings released on 30 Jul 2025
EPS came in at $0.10 surpassing the estimated $0.06 by +66.67%, while revenue for the quarter reached $98.61M , beating expectations by +5.66%.
Earnings released on 30 Apr 2025
EPS came in at $0.06 matching the estimated $0.06, while revenue for the quarter reached $88.21M , beating expectations by +2.18%.
Earnings released on 26 Feb 2025
EPS came in at $0.07 matching the estimated $0.07, while revenue for the quarter reached $92.91M , beating expectations by +3.90%.
Earnings released on 30 Oct 2024
EPS came in at $0.05 surpassing the estimated $0.04 by +13.64%, while revenue for the quarter reached $84.06M , missing expectations by -6.00%.
Earnings released on 31 Jul 2024
EPS came in at $0.08 matching the estimated $0.08, while revenue for the quarter reached $87.21M , missing expectations by -1.93%.
Earnings released on 30 Apr 2024
EPS came in at $0.07 surpassing the estimated $0.05 by +40.00%, while revenue for the quarter reached $84.71M , beating expectations by +6.74%.
Earnings released on 28 Feb 2024
EPS came in at $0.04 falling short of the estimated $0.08 by -50.00%, while revenue for the quarter reached $86.83M , beating expectations by +2.10%.
Earnings released on 30 Oct 2023
EPS came in at $0.06 surpassing the estimated $0.05 by +20.00%, while revenue for the quarter reached $81.71M , missing expectations by -3.92%.
Earnings released on 1 Aug 2023
EPS came in at $0.01 surpassing the estimated $0.01 by +100.00%, while revenue for the quarter reached $81.26M , beating expectations by +8.59%.
Earnings released on 2 May 2023
EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%, while revenue for the quarter reached $71.68M , beating expectations by +11.73%.
Earnings released on 1 May 2023
EPS came in at -$0.00 , while revenue for the quarter reached $74.38M .
Earnings released on 2 Nov 2022
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $67.69M , beating expectations by +1.44%.
Earnings released on 2 Aug 2022
EPS came in at -$0.11 falling short of the estimated -$0.06 by -83.33%, while revenue for the quarter reached $66.88M , beating expectations by +2.79%.
Earnings released on 3 May 2022
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%, while revenue for the quarter reached $58.89M , beating expectations by +8.86%.
Earnings released on 28 Feb 2022
EPS came in at $0.01 surpassing the estimated $0.00 by +129.89%, while revenue for the quarter reached $67.41M , beating expectations by +5.84%.
Earnings released on 2 Nov 2021
EPS came in at -$0.04 surpassing the estimated -$0.08 by +50.00%, while revenue for the quarter reached $63.07M , beating expectations by +4.67%.
Earnings released on 3 Aug 2021
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%, while revenue for the quarter reached $68.17M , beating expectations by +15.99%.
Earnings released on 28 Apr 2021
EPS came in at -$0.09 surpassing the estimated -$0.19 by +52.63%, while revenue for the quarter reached $59.97M , missing expectations by -27.20%.
Earnings released on 8 Mar 2021
EPS came in at -$0.17 falling short of the estimated -$0.05 by -240.00%, while revenue for the quarter reached $68.55M .
Earnings released on 4 Nov 2020
EPS came in at -$0.48 , while revenue for the quarter reached $64.30M .
MDXG Stock Performance
Access detailed MDXG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.